Controversies in Treating Early HR-Positive Breast Cancer

Article

This video reviews controversies in the treatment of early-stage hormone receptor (HR)-positive breast cancer.

In this video, Vered Stearns, MD, of Johns Hopkins School of Medicine in Baltimore, Maryland, reviews controversies in the treatment of early-stage hormone receptor (HR)-positive breast cancer.

Stearns gave a presentation on this topic at the 2017 San Antonio Breast Cancer Symposium (SABCS), held December 5–9 in San Antonio, Texas.

Recent Videos
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Related Content